Quantitative characterization of UDP-glucuronosyltransferase 2B17 in human liver and intestine and its role in testosterone first-pass metabolism
- 1 October 2018
- journal article
- research article
- Published by Elsevier in Biochemical Pharmacology
- Vol. 156, 32-42
Abstract
No abstract availableKeywords
Funding Information
- NIH (R01 HD081299)
- Department of Pharmaceutics, University of Washington
This publication has 51 references indexed in Scilit:
- UGT2B17 Polymorphism and Risk of Prostate Cancer: A Meta-AnalysisISRN Oncology, 2013
- UGT2B17 Genetic Polymorphisms Dramatically Affect the Pharmacokinetics of MK-7246 in Healthy Subjects in a First-in-Human StudyClinical Pharmacology & Therapeutics, 2012
- Homozygous deletion of the UGT2B17 gene is not associated with osteoporosis risk in elderly Caucasian womenOsteoporosis International, 2010
- Quantitative Evaluation of the Expression and Activity of Five Major Sulfotransferases (SULTs) in Human Tissues: The SULT “Pie”Drug Metabolism and Disposition, 2009
- Genome-wide Copy-Number-Variation Study Identified a Susceptibility Gene, UGT2B17, for OsteoporosisThe American Journal of Human Genetics, 2008
- Adaptive Evolution of UGT2B17 Copy-Number VariationThe American Journal of Human Genetics, 2008
- Doping Test Results Dependent on Genotype of Uridine Diphospho-Glucuronosyl Transferase 2B17, the Major Enzyme for Testosterone GlucuronidationThe Journal of Clinical Endocrinology & Metabolism, 2008
- Gut instincts: CYP3A4 and intestinal drug metabolismJournal of Clinical Investigation, 2007
- Review of oxymetholone: a 17α-alkylated anabolic-androgenic steroidClinical Therapeutics, 2001
- Oral Testosterone, a ReappraisalHormone Research, 1978